Stockscreener 앱 받기
3.70
1.09%
0.04
시간 외 거래:
3.75
0.05
+1.35%
Cosciens Biopharma Inc 주식(CSCI)의 최신 뉴스
COSCIENS Biopharma Sets Date for Annual Meeting Amid Strategic Shifts - TipRanks
Fennec Pharmaceuticals: Top 10 Undervalued Biotechnology Industry Stocks (FRX) - The Globe and Mail
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
COSCIENS Biopharma appoints Anna Biehn as new CEO amid leadership change - N24.com.tr
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Bi - GuruFocus
COSCIENS Biopharma (CSCI) Names Anna Biehn as New CEO | CSCI Sto - GuruFocus
COSCIENS Biopharma names new CEO Anna Biehn By Investing.com - Investing.com Canada
COSCIENS Biopharma names new CEO Anna Biehn - Investing.com Australia
COSCIENS Biopharma names Anna Biehn as new CEO By Investing.com - Investing.com South Africa
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$1.89 loss in FY 2023) - simplywall.st
COSCIENS Biopharma names Anna Biehn as new CEO - Investing.com Australia
Cosciens Biopharma appoints Biehn as CEO - TipRanks
COSCIENS Biopharma Appoints Anna Biehn as New CEO to Drive Growth in Natural-Based Products - TipRanks
Cosciens Biopharma Appoints Anna Biehn as Chief Executive Officer - marketscreener.com
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer - The Manila Times
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023) - Yahoo Finance
COSCIENS Biopharma Reports Revenue Growth and Strategic Repositioning - MSN
Cosciens Biopharma Charts New Path Following Ceapro Merger - Finimize
COSCIENS Biopharma reports Q4 and full year 2024 results - Investing.com Australia
COSCIENS Biopharma: Q4 Earnings Snapshot - CT Insider
COSCIENS Biopharma reports Q4 and full year 2024 results By Investing.com - Investing.com South Africa
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 202 - GuruFocus
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
Natural Products Drive COSCIENS Growth: Revenue Jumps 35% as Pipeline Advances - Stock Titan
COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays - TipRanks
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Lelezard
COSCIENS Biopharma Faces Trading Halt: What Investors Need to Know - AInvest
Regulatory Alert: COSCIENS Faces Management Trading Ban Over Missing Financial Reports - Stock Titan
Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? - Insider Monkey
COSCIENS Biopharma flags potential reporting delay By Investing.com - Investing.com Australia
Thursday’s 10 Worst-Performing Stocks - Insider Monkey
Sector Update: Health Care Stocks Edge Higher Late Afternoon -March 20, 2025 at 04:02 pm EDT - MarketScreener
Top Midday Decliners -March 20, 2025 at 02:10 pm EDT - MarketScreener
COSCIENS Biopharma flags potential reporting delay - Investing.com
COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger Complexities - TipRanks
0.39%
3.66%
자본화:
|
볼륨(24시간):